The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Gomez, Christopher M.
PropertyValue
overview Christopher M. Gomez MD PhD has worked in the field of genetic disorders of the neuromuscular junction (congenital myasthenic syndromes) and cerebellum for more than 25 years. Dr. Gomez’s long term goals are to help characterize the pathogenic mechanisms that cause ataxia, develop treatments and to identify disease and stage-specific biomarkers of ataxia. Dr. Gomez is an expert in neurogenetic disorders, gait and balance disorders, and in the diagnosis and treatment of patients with ataxias -- a family of rare neurodegenerative diseases. Since 1991, Dr. Gomez has been on the medical and research advisory board of the National Ataxia Foundation. He is past chair of the Neurogenetics Section of the American Academy of Neurology. Dr. Gomez's laboratory research concentrates on the molecular and cellular mechanisms of neurodegenerative disease--with a focus on the means by which genetic mutations in ion channels or other essential proteins lead to dominantly inherited neurodegenerative diseases. His research has resulted in more than 50 peer-reviewed publications in scientific journals. Dr. Gomez established The University of Chicago Ataxia Center in 2006 as a specialty clinic and research center devoted to the diagnosis, treatment, and management of ataxias, and as focal points for translational and clinical research. Dr. Gomez has over 20 years of expertise in the evaluation and treatment of patients with diverse forms of degenerative ataxia. Dr. Gomez is a founding member of the Cooperative Ataxia Group, a national consortium of ataxia specialists that launched the fi rst rating scale and natural history studies for Friedreich’s Ataxia (D. Lynch, PI). He is also a member (UC site) of the newly funded Rare Disease Clinical Research Network for Autosomal Dominant Ataxias (T. Ashizawa, PI). By assembling teams composed of physiologists, neuro-imagers and geneticists, Dr. Gomez has been involved since 1993 in genetic, phenotypic, and genotype-phenotype and studies of patients with a wide range of ataxia types. Dr. Gomez helped characterize spinocerebellar ataxia type 6 (SCA6) and episodic ataxia type 2 and discovered SCA26. In the laboratory Dr. Gomez studies the disease process caused by the SCA6 and SCA26 mutations and looks for disease and stage-specific biomarkers cerebrospinal fluid of SCA patients.
One or more keywords matched the following items that are connected to Gomez, Christopher M.
Item TypeName
Concept Ion Channels
Concept Calcium Channels
Concept Calcium Channels, P-Type
Concept Calcium Channels, N-Type
Concept Calcium Channels, Q-Type
Concept Shaw Potassium Channels
Concept Calcium Channels, L-Type
Academic Article A transgenic mouse model of the slow-channel syndrome.
Academic Article Stable respiratory activity requires both P/Q-type and N-type voltage-gated calcium channels.
Academic Article Further evidence for the role of IP 3R 1 in regulating subsynaptic gene expression and neuromuscular transmission.
Academic Article Spinocerebellar ataxia type 6.
Academic Article Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6.
Academic Article Dominant-negative suppression of Cav2.1 currents by alpha(1)2.1 truncations requires the conserved interaction domain for beta subunits.
Academic Article Molecular pathogenesis of spinocerebellar ataxia type 6.
Academic Article Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6.
Academic Article Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13).
Academic Article The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes.
Academic Article C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity.
Academic Article Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation.
Academic Article Impaired eye movements in presymptomatic spinocerebellar ataxia type 6.
Academic Article Revelations from a bicistronic calcium channel gene.
Academic Article A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome.
Academic Article Polyglutamine aggregates in SCA6 Purkinje cells: a tail of two toxicities.
Academic Article Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels.
Academic Article Novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits.
Academic Article DnaJ-1 and karyopherin a3 suppress degeneration in a new Drosophila model of Spinocerebellar Ataxia Type 6.
Academic Article An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron.
Academic Article Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6.
Academic Article Targeting the CACNA1A IRES as a Treatment for Spinocerebellar Ataxia Type 6.
Academic Article Spinocerebellar [corrected] Ataxia Type 6: Molecular Mechanisms and Calcium Channel Genetics.
Academic Article a1ACT Is Essential for Survival and Early Cerebellar Programming in a Critical Neonatal Window.
Search Criteria
  • Hyperpolarization Activated Cyclic Nucleotide Gated Channels